|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Denver M. Lough||Chairman, CEO and Chief R&D Officer (On indefinite administrative leave)||N/D||N/D||1981|
|Mr. Paul Elliot Mann||Chief Financial Officer||N/D||N/D||N/D|
|Mr. Richard Hague||Chief Operating Officer||N/D||N/D||1960|
|Dr. David Blum||Chief Design & Technology Officer||N/D||N/D||N/D|
|Mr. Nikolai Sopko||Chief Scientific Officer and VP of R&D||N/D||N/D||N/D|
PolarityTE, Inc., a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.
L'ISS Governance QualityScore di PolarityTE, Inc. al 29 luglio 2019 è 10. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 8; diritti degli azionisti: 7; retribuzione: 10.